Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (8427)	1/22/1999 3:32:00 PM
From: aknahow	Read Replies (3) \| Respond to of 17367

From the ABTI release: "The confirmatory Phase III study was designed to verify the efficacy and safety of 1.0 mg/kg Betafectin in patients undergoing upper (non-colorectal) GI surgeries who are at risk of post-operative infections. The double-blind, placebo-controlled study involved 618 patients at 30 sites throughout the United States. The primary clinical endpoint for the study was a reduction in the proportion of patients who develop serious infections or death following surgery. Secondary endpoints included length of hospital stay, number of intensive care unit days, days of antibiotic use, and mortality." BTW I think the fact that the trial was discontinued at about the halfway point is an indication that continuation as seen in the XOMA trial is not a negative event.